vTv Therapeutics to Present Posters at Two Scientific Conferences in September
September 11 2019 - 7:30AM
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage
biopharmaceutical company with leading programs focused on the
development of orally administered treatments for diabetes,
Alzheimer’s disease and inflammatory disorders, today announced it
will be presenting posters with new clinical and pre-clinical data
from the company’s Liver Selective GKA Program and its NRF2/Bach1
program at two upcoming European scientific conferences.
Details of the posters are listed below:
55th Annual Meeting of the European Association for the
Study of DiabetesThe conference is being held in
Barcelona, Spain from September 16-20, 2019
- Poster Title: Results from the sentinel and
learning Phase of the Simplici-T1 study, the First Clinical Trial
to Test Activation of Glucokinase as an Adjunctive Treatment for
Type 1 Diabetes
- Poster Number: 729
- Date and Time: Wednesday, September 18,
13:15-14:15 CEST
EASL Non-Alcoholic Fatty Liver Disease (NAFLD) Summit
2019The conference is hosted by The European Association
for the Study of the Liver (EASL) being held in Seville, Spain from
September 26-28, 2019
- Poster Title: Non-electrophilic activation of
the NRF2 pathway ameliorated experimental Nonalcoholic
Steatohepatitis
- Abstract Number: 173
- Date and Time: Sept 28, 2019, 10:25-10:45
CEST
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on developing oral small molecule drug candidates.
vTv has a pipeline of clinical drug candidates led by programs for
the treatment of diabetes, Alzheimer’s disease, and inflammatory
disorders. vTv’s development partners are pursuing additional
indications in type 2 diabetes, Chronic Obstructive Pulmonary
Disease (COPD), and genetic mitochondrial diseases.
ContactsInvestors: vTv Therapeutics Inc.
IR@vtvtherapeutics.com
or Media:Josh Vlasto212-572-5969PR@vtvtherapeutics.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024